Factors Contributing to Increases in Prescription Drug Expenditures Borne by National Health Insurance in South Korea

다국어 초록 (Multilingual Abstract)

Purpose: Rapid growth of prescription drug expenditures is a problem in South Korea. The objective of this study was to assessthe contributions of four variables (therapeutic choice, drug-mix, original use, and price changes) to increases in drug expenditurespaid by the National Health Insurance (NHI) in Korea.
Materials and Methods: A retrospective cohort study was conducted between January 1, 2008 and June 30, 2012 utilizing datafrom the NHI Claims Database of the Health Insurance Review and Assessment Service. The number of target drug types for finalanalysis was 13959. To analyze the growth rates of drug expenditures, this study used Fisher ideal index and the Laspeyres and Paascheindexes.
Results: With the exception of 2012, therapeutic choice contributed to about 40–60% of the increase in drug expenditures everyyear, while drug-mix contributed to another 30–40%.
Conclusion: The rapid growth in prescription drug expenditure was found to be largely due to drug-mix and therapeutic choiceover time. Original use had little impact on drug spending.

참고문헌 (Reference)

1 이인향, "한국 국민건강보험시장에서의 제네릭 의약품 사용 양상과 영향 요인" 대한약학회 58 (58): 99-106, 2014

2 배은영, "약제비 증가의 기여 요인과 영향 분석" 한국보건경제정책학회 13 (13): 39-54, 2007

3 정인석, "약제비 관리방안으로서 저가구매 인센티브 제도" 한국보건사회연구원 29 (29): 243-267, 2009

4 최윤정, "건강보험 약품비 증가의 주요 요인분석" 한국보건정보통계학회 36 (36): 15-24, 2011

5 Prieto L, "The new EMCDDA standard table on public expenditure:a step forward in quantifying drug-related costs in Europe" 10 : S211-, 2009

6 Shin Y, "The National Health Insurance and its policy tasks" Korea Institute for Health and Social Affairs 2010

7 Lee YK, "Separation of prescription and dispensing: changes in pharmaceutical costs and related policy issues" Korea Institute for Health and Social Affairs 2001

8 Morgan SG, "Quantifying components of drug expenditure inflation:the British Columbia seniors’ drug benefit plan" 37 : 1243-1266, 2002

9 OECD, "Health at a glance 2011: OECD indicators" OECD Publishing; 2013

10 Park SE, "Evaluation on the first 2 years of the positive list system in South Korea" 104 : 32-39, 2012

11 Ministry of Health and Welfare, "Evaluation of price cuts for drugs whose patents are expired after one year" Ministry of Health and Welfare

12 Ess SM, "European healthcare policies for controlling drug expenditure" 21 : 89-103, 2003

13 Bae G, "Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea" 14 : 100-, 2014

14 Morgan S, "Drug expenditure trends in the Canadian provinces:magnitude and causes from 1998 to 2004" 1 : 85-99, 2005

15 Jang S, "Determinants of publicly funded drug expenditure in South Korea" Health Insurance Review & Assessment Service 2011

16 Chernew ME, "Decomposing pharmaceutical cost growth in different types of health plans" 7 : 667-673, 2001

17 IMS Health intelligence applied, "Benchmarking prescribing behaviour for 207 disease conditions in Korea against those in specific reference markets, and to explore the drivers of any disparities in prescribing behaviour"

18 National Health Insurance Service, "2012 National Health Insurance statistical yearbook" National Health Insurance Service, Health Insurance Review & Assessment Service 2013

19 Park M, "2010 Survey on National Health Insurance out-of-pocket expenditure" National Health Insurance Service Health Insurance Police Research Institute 2011